NCT06523673View on ClinicalTrials.gov

Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Metastatic Non-Small Cell Lung CancerNSCLC Stage IVOligoProgressive Metastatic Disease
Interventions
RADIATION

Stereotactic Body Radiotherapy

The dose of radiation therapy is determined by the radiologist based on the clinical parameters of the lesion, including tumor size and location. In most cases, radiotherapy fractionation regimens range from 27-30 Gy/3 Fractions or 30-50 Gy/5 Fractions, and appropriate radiotherapy doses covering 27-70 Gy/3-10 Fractions can also be selected by the radiologist based on radiation limitations of neighboring endangered organs.

DRUG

second-line systemic therapy

a second-line docetaxel/albumin-bound paclitaxel-based systemic therapy regimen

Trial Locations (1)

Unknown

RECRUITING

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER